Literature DB >> 29337044

Lysophosphatidic acid regulates the motility of MCF10CA1a breast cancer cell sheets via two opposing signaling pathways.

Christina H Stuelten1, Rachel M Lee2, Wolfgang Losert2, Carole A Parent3.   

Abstract

Aberrant cell migration leads to the dispersal of malignant cells. The ubiquitous lipid mediator lysophosphatidic acid (LPA) modulates cell migration and is implicated in tumor progression. Yet, the signaling cascades that regulate LPA's effect on cell motility remain unclear. Using time-lapse imaging and quantitative analyses, we studied the role of signaling cascades that act downstream of LPA on the motility of MCF10CA1a breast cancer cells. We found that LPA alters cell motility via two major signaling pathways. The Rho/ROCK signaling cascade is the predominant pathway that increases E-Cadherin containing cell-cell adhesions and cortical arrangement of actomyosin to promote slow, directional, spatially coherent and temporally consistent movement. In contrast, Gαi/o- and Gαq/11-dependent signaling cascades lessen directionality and support the independent movement of cells. The net effect of LPA on breast cancer cell migration therefore results from the integrated signaling activity of the Rho/ROCK and Gαi/o- and Gαq/11-dependent pathways, thus allowing for a dynamic migratory response to changes in the cellular or microenvironmental context. Published by Elsevier Inc.

Entities:  

Keywords:  Breast cancer; Cell motility; Lysophosphatidic acid; Sheet migration; Signal transduction

Mesh:

Substances:

Year:  2018        PMID: 29337044      PMCID: PMC5845779          DOI: 10.1016/j.cellsig.2018.01.005

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  58 in total

Review 1.  Autotaxin and LPA receptor signaling in cancer.

Authors:  Anna J S Houben; Wouter H Moolenaar
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

2.  Increased chemoresistance to paclitaxel in the MCF10AT series of human breast epithelial cancer cells.

Authors:  Soo-Jeong Lim; Hyeon Gyeom Choi; Chae Kyung Jeon; So Hee Kim
Journal:  Oncol Rep       Date:  2015-02-02       Impact factor: 3.906

3.  The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases.

Authors:  Ahmed Boucharaba; Claire-Marie Serre; Julien Guglielmi; Jean-Claude Bordet; Philippe Clézardin; Olivier Peyruchaud
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-12       Impact factor: 11.205

4.  LPA(1) -induced migration requires nonmuscle myosin II light chain phosphorylation in breast cancer cells.

Authors:  Jong Hyun Kim; Robert S Adelstein
Journal:  J Cell Physiol       Date:  2011-11       Impact factor: 6.384

Review 5.  Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays.

Authors:  Semjon Willier; Elke Butt; Thomas G P Grunewald
Journal:  Biol Cell       Date:  2013-06-03       Impact factor: 4.458

6.  Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway.

Authors:  Dafang Bian; Shibing Su; Chitladda Mahanivong; Robert K Cheng; Qiwei Han; Zhixing K Pan; Peiqing Sun; Shuang Huang
Journal:  Cancer Res       Date:  2004-06-15       Impact factor: 12.701

7.  Aberrant expression of lysophosphatidic acid (LPA) receptors in human colorectal cancer.

Authors:  Dai Shida; Toshiaki Watanabe; Junken Aoki; Kotaro Hama; Joji Kitayama; Hirofumi Sonoda; Yasuhiro Kishi; Hironori Yamaguchi; Shin Sasaki; Akihiro Sako; Tsuyoshi Konishi; Hiroyuki Arai; Hirokazu Nagawa
Journal:  Lab Invest       Date:  2004-10       Impact factor: 5.662

8.  Lysophosphatidic acid induces MDA-MB-231 breast cancer cells migration through activation of PI3K/PAK1/ERK signaling.

Authors:  Jun Du; Chongqi Sun; Zhenzhen Hu; Yu Yang; Yichao Zhu; Datong Zheng; Luo Gu; Xiang Lu
Journal:  PLoS One       Date:  2010-12-30       Impact factor: 3.240

9.  Association of Rho-associated protein kinase 1 with E-cadherin complexes is mediated by p120-catenin.

Authors:  Andrew L Smith; Michael R Dohn; Meredith V Brown; Albert B Reynolds
Journal:  Mol Biol Cell       Date:  2011-10-26       Impact factor: 4.138

10.  An operational view of intercellular signaling pathways.

Authors:  Yaron E Antebi; Nagarajan Nandagopal; Michael B Elowitz
Journal:  Curr Opin Syst Biol       Date:  2017-02-24
View more
  6 in total

Review 1.  Dynamics phenotyping across length and time scales in collective cell migration.

Authors:  Rachel M Lee; Wolfgang Losert
Journal:  Semin Cell Dev Biol       Date:  2018-10-31       Impact factor: 7.727

2.  Serum ATX as a novel biomarker for breast cancer.

Authors:  Yingbo Shao; Yang Yu; Yaning He; Qi Chen; Hui Liu
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

Review 3.  Role of lysophosphatidic acid and its receptors in health and disease: novel therapeutic strategies.

Authors:  Luiz Henrique Medeiros Geraldo; Tânia Cristina Leite de Sampaio Spohr; Rackele Ferreira do Amaral; Anna Carolina Carvalho da Fonseca; Celina Garcia; Fabio de Almeida Mendes; Catarina Freitas; Marcos Fabio dosSantos; Flavia Regina Souza Lima
Journal:  Signal Transduct Target Ther       Date:  2021-02-01

4.  CMTM8 as an LPA1-associated partner mediates lysophosphatidic acid-induced pancreatic cancer metastasis.

Authors:  Weidong Shi; Chenyue Zhang; Zhouyu Ning; Yongqiang Hua; Ye Li; Lianyu Chen; Luming Liu; Zhen Chen; Zhiqiang Meng
Journal:  Ann Transl Med       Date:  2021-01

5.  Distinct roles of tumor associated mutations in collective cell migration.

Authors:  Rachel M Lee; Michele I Vitolo; Wolfgang Losert; Stuart S Martin
Journal:  Sci Rep       Date:  2021-05-13       Impact factor: 4.996

6.  RhoA-ROCK competes with YAP to regulate amoeboid breast cancer cell migration in response to lymphatic-like flow.

Authors:  Amina Mohammadalipour; Miguel F Diaz; Megan Livingston; Adesuwa Ewere; Allen Zhou; Paulina D Horton; Loretta T Olamigoke; John M Lamar; John P Hagan; Hyun J Lee; Pamela L Wenzel
Journal:  FASEB Bioadv       Date:  2022-02-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.